Fig. 1. (A)
Serum soluble VE-cadherin levels in patients with various skin diseases. The serum levels of VE-cadherin determined by using ELISA are shown on the ordinate; the horizontal bars show the mean value in each group. The dotted line indicates the cutoff. VE: vascular endothelial, NS: normal subjects. AD: atopic dermatitis, Pso: psoriasis, AA: alopecia areata, AP: anaphylactoid purpura, PNc: cutaneous polyarteritis nodosa, AS: angiosarcoma. *p＜0.05 by using the Mann-Whitney U-test. (B) Receiver operating characteristic curve for serum VE-cadherin levels in patients with AD. AUC: areas under curves, SE: standard error, CI: confidence interval. (Fig. 1A) . The mean serum VE-cadherin level tended to be lower in patients with AD (1.903 μg/ml) and those with psoriasis (1.915 μg/ml) in comparison to normal subjects (2.511 μg/ml). We found a statistical significance in these decreases (p=0.01 in patients with AD, and p=0.04 in patients with psoriasis). The serum VE-cadherin levels in patients with alopecia (p=0.81), anaphylactoid purpura (p=0.90), cutaneous polyarteritis nodosa (p=0.96), or angiosarcoma (p=0.13) were similar to those in normal subjects. When the cutoff value was set at 1.880 μg/ml on the basis of the normal range provided by the manufacturer, reduced serum VE-cadherin levels were found in 3 of the 18 healthy volunteers (16.7%), 8 of the 13 patients with AD (61.5%), 16 of the 33 patients with psoriasis (48.5%), 1 of the 7 patients with alopecia (14.3%), 4 of the 12 patients with anaphylactoid purpura (33.3%), 2 of the 11 patients with cutaneous polyarteritis nodosa (11.2%), and 0 of the 6 patients with angiosarcoma. Thus, the low serum VEcadherin levels may be more specific to AD or psoriasis than cutaneous vasculitis or vascular tumor. In the receiver operating characteristic curve analysis of patients with AD (Fig. 1B) , the area under curve (AUC) was 0.77 (95% confidence interval [95% CI], 0.59~0.96). An AUC of ＞0.7 indicates that the serum VE-cadherin levels can effectively distinguish patients with AD from normal subjects. On the other hand, the AUC was 0.67 (95% CI, 0.53~0.82) in patients with psoriasis, indicating that serum VE-cadherin is less useful in diagnosing psoriasis. Accordingly, serum VE-cadherin may be more effective for diagnosing AD than psoriasis. Next, we determined the association of serum VE-cadherin levels with the clinical and serological features of patients with AD (Table 1) ; 5 disease activity markers (SCORAD, percentage of eosinophil counts, serum lactate dehydrogenase levels, serum thymus and activation-regulated chemokine levels, and serum immunoglobulin E level) and the duration of the disease (between symptom onset and the first visit to the hospital) were evaluated. However, we could not find a significant difference in these factors between patients with reduced VE-cadherin levels and those with normal levels. On the other hand, in patients with psoriasis, when 4 activity indicators (psoriasis area and severity index score, body surface area of the involved skin, arthritis, and nail change) and disease duration were evaluated (Table 1) , patients with reduced VE-cadherin levels showed a significantly lower prevalence of nail change (p=0.03). Thus, serum VE-cadherin levels are correlated with clinical symptom in patients with psoriasis but not in patients with AD. Taken together, our results suggest that the serum VE-cadherin level in patients with AD can be the diagnostic marker rather than the disease activity marker, whereas that in patients with psoriasis may be more useful as the marker for disease activity. This is the first report measuring serum VE-cadherin levels in patients with various skin diseases. Furthermore, as far as we searched, decreased serum VE-cadherin levels have not been reported in human diseases. Although the role of VE-cadherin in skin diseases is unknown, skin erythema, for example, is one of the common features of AD and psoriasis and is caused by dilated vessels. As described above, soluble VE-cadherin may function as an antagonist of full-length VE-cadherin. Thus, lower serum soluble VE-cadherin levels may activate transmembrane full-length VE-cadherin, which may contribute to the pathogenesis of AD and psoriasis through erythema formation. Clarifying the mechanism by which VE-cadherin-mediated vascular abnormality contributes to the pathogenesis may lead to the understanding of these diseases and to novel therapeutic strategies. However, this study has a limitation; although the VE-cadherin levels were lower in patients with psoriasis than in healthy volunteers, the nail change is less frequent in patients with psoriasis with decreased VE-cadherin levels. This paradoxical finding may be due to the small number of patients. A larger study with an increased number of patients is needed in the future.
